We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Cognitive ADHD Videogame Exploratory Study (CAVES)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01943539
Recruitment Status : Completed
First Posted : September 17, 2013
Results First Posted : December 13, 2017
Last Update Posted : December 13, 2017
Information provided by (Responsible Party):
Akili Interactive Labs, Inc.

Brief Summary:
A study in ADHD and neuro-typical children to assess EVO game play over 29 days.

Condition or disease Intervention/treatment Phase
Attention Deficit Hyperactivity Disorder Device: Neuro-typical controls and ADHD will receive EVO game play. Not Applicable

Detailed Description:

A study in children ages 8 to 12 to assess EVO cognitive game play. The study examines two populations, children diagnosed with ADHD (ADHD and not on medication) and neuro-typical children. The investigators plan to evaluate 80 subjects (N = 40 per group) in three site locations over a 29 day study period. The 29 day study period includes 2 in-clinic sessions and 27 days of out-patient game play. During the 27 days of out-patient game play, the subjects will be instructed to play EVO 5 days per week for typically 30 minutes per day

The investigators' hypothesis is that EVO will be playable and interesting to ADHD children and cognitive measures, as captured by EVO, will show a difference between ADHD children and age-matched neuro-typical children.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 84 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study to Assess the Feasibility of EVO Gameplay to Engage Children With Attention Deficit Hyperactivity Disorder (ADHD) and to Evaluate Cognitive Interference in Children Ages 8 to 12 Years Old With ADHD Compared to Neuro-typical Children
Study Start Date : September 2013
Actual Primary Completion Date : May 2015
Actual Study Completion Date : May 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: EVO Game Play
Neuro-typical controls and ADHD will receive EVO game play.
Device: Neuro-typical controls and ADHD will receive EVO game play.
EVO mobile video application

Primary Outcome Measures :
  1. Reaction Time in EVO Gameplay [ Time Frame: 28 days ]
    EVO employs a perceptual discrimination attention/memory task as well as a continuous visuomotor "driving" task. Subjects were instructed to target a pre-specified stimulus, and ignore all other stimuli while navigating a road-like course. Reaction time was measured as the time between the initial presentation of the pre-specified target and when the subject tapped the tablet screen. Longer reaction times indicated a larger deficit in multitasking.

  2. Number of Participants With Non-Treatment Related Adverse Events [ Time Frame: Day 0 through Day 28 of the study ]
    Another objective of this study is to evaluate the safety of EVO game play based on treatment-emergent adverse events (TEAEs) that may occur during this 28-day period of time.

Secondary Outcome Measures :
  1. Time Spent Completing the Intervention [ Time Frame: 28 days ]
    Time spent on completing the intervention is based on the prescribed therapy of 800 total minutes, or 13.3 hours, over the course of 28 days (7 sessions of EVO per day for 5 days per week for 4 weeks with each session lasting approximately 5.7 minutes long).

Other Outcome Measures:
  1. Mean of Differences in TOVA Attention Performance Index (API) at Baseline (Day 0) and at Day 28 [ Time Frame: Day 0 and Day 28 ]

    TOVA API is a comparison of the subject's scores based on selected measures that persons with an independent diagnosis of ADHD frequently demonstrated. The API is calculated from variability, response time, and D' (D Prime) using the following formula:

    API = Response Time Z score (Half 1) + D' Z score (Half 2) + Variability Z score (Total) + 1.80

    where Response Time is the average time it takes to respond correctly to a target, d' (D Prime) score is a response discriminability score reflecting the ratio of hits to "false alarms", and Variability is a measure of consistency of speed of responding based on the standard deviation of the mean correct response times. API tells how similar the score is to the ADHD profile. A score of less than -1.8 indicates that the subject had similar performance to a normative ADHD population. A lower score indicates a more severe ADHD profile.

    The calculation for difference in TOVA API was API at Baseline (Day 0) minus API at Day 28.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   8 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Age 8 to 12 at the time of parental informed consent.
  2. Confirmed ADHD diagnosis at clinic per MINI-Kid (ADHD Cohort)
  3. Baseline ADHD-RS-IV score >= 24 (ADHD Cohort), obtained at clinic
  4. Baseline ADHD-RS-IV score <=13 (Neuro-typical Cohort), obtained at clinic
  5. Consistently off ADHD drug for 1 week. Drugs include: Pre specified, oral psychostimulants (ADDERALL XR® [mixed salts of a single-entity amphetamine product], VYVANSE® [lisdexamfetamine dimesylate], CONCERTA® [methylphenidate HCl], FOCALIN XR® [dexmethylphenidate HCl], RITALIN LA® [methylphenidate HCl extended-release], METADATE CD® [methylphenidate HCl, USP], or FDA-approved generic equivalents )for 1 month (Other than ADHD drud
  6. Consistently off Psychotropic drug for 1 month (Other than ADHD drug noted above)
  7. Ability to follow written and verbal instructions (English)
  8. Girls or Boys (Gender-matched - 30% girls minimum)
  9. Functioning at an age-appropriate level intellectually.
  10. Ability to comply with all the testing and requirements.

Exclusion Criteria:

  1. Current, controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as post-traumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder, conduct disorder, or other symptomatic manifestations that in the opinion of the Investigator that may confound study data/assessments (per MINI-Kid).
  2. Within the last 4 weeks, subject has entered or exited behavioral therapy. The subject should inform the Investigator if they intend to change their behavioral therapy during the 4 weeks of the study.
  3. Subject is currently considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or has a prior history of, or is currently demonstrating active suicidal ideation or self-injurious behavior (per C-SSRS).
  4. History of failure to respond to an adequate trial of 2 treatments for ADHD (consisting of an appropriate dose and adequate duration of therapy and failure in efficacy in the opinion of the Investigator).
  5. Motor condition that prevents game playing
  6. Recent history (within the past 6 months) of suspected substance abuse or dependence.
  7. History of seizures (exclusive of febrile seizures), a tic disorder, significant tics, or a current diagnosis of Tourette's Disorder.
  8. Taken part in a clinical trial within 30 days prior to screening.
  9. Diagnosis of color blindness
  10. Regular use of psychoactive drugs that in the opinion of the Investigator may confound study data/assessments.
  11. Any other medical condition that in the opinion of the Investigator may confound study data/assessments.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01943539

Layout table for location information
United States, Florida
Florida Clinical Research Center, LLC
Bradenton, Florida, United States, 32401
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Akili Interactive Labs, Inc.
Layout table for investigator information
Principal Investigator: Andrew J Cutler, MD Florida Clinical Research Center, LLC
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Akili Interactive Labs, Inc.
ClinicalTrials.gov Identifier: NCT01943539    
Other Study ID Numbers: Akili-001
First Posted: September 17, 2013    Key Record Dates
Results First Posted: December 13, 2017
Last Update Posted: December 13, 2017
Last Verified: November 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Neurologic Manifestations
Nervous System Diseases